Dare Bioscience, Inc. DARE
Dare Bioscience, Inc. (Nasdaq: DARE) is an endocrine/women's health drug developer. Its lead program, Ovaprene, is in Phase 3 for hormone-free monthly intravaginal contraception. Its next catalyst on record is Ovaprene: Top-line data from pivotal Phase 3 study (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Ovaprene — Top-line data from pivotal Phase 3 study (2027). 2 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Ovaprene | contraception | device-combination | Phase 3 |
| Sildenafil Cream, 3.6% | female sexual arousal disorder (FSAD) | small molecule | Phase 2 |
| DARE-HRT1 | moderate to severe vasomotor symptoms of menopause | device-combination | Phase 2 |
| DARE-VVA1 | dyspareunia (vulvovaginal atrophy) | small molecule | Phase 2 |
| DARE-HPV | persistent high-risk HPV infection / CIN | small molecule | Phase 2 |
| DARE-LARC1 | long-acting reversible contraception | device-combination | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.